ipo
Stage
2
Investors
About
Alumis Inc. is developing next-generation targeted therapies for immune-mediated diseases, advancing a late-stage portfolio (including envudeucitinib) and using a proprietary data analytics platform to support precision therapeutic development.
Explore Alumis Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.